Zimelidine is an antidepressant , a selective serotonin reuptake inhibitor . Currently discontinued.
| Zimelidine | |
|---|---|
 | |
| Chemical compound | |
| IUPAC | ( Z ) -3- (4-bromophenyl) - N, N- dimethyl-3- (pyradin-3-yl) prop-2-en-1-amine |
| Gross formula | C 16 H 17 BrN 2 |
| Molar mass | 317,224 |
| Cas | |
| PubChem | |
| Drugbank | |
| Classification | |
| Farmakol. Group | Antidepressants |
| ATX | |
| Route of administration | |
| orally | |
| Other names | |
| Zimeldin, Normood, Zelmid | |
Content
History
Zimelidine was developed in the late 1970s and early 1980s by Arvid Karlsson , who worked at the time in the Swedish pharmaceutical company AstraZeneca .
An antidepressant was discovered after searching for drugs with a structure similar to brompheniramine , an antihistamine in the propylamine family (alkylamines). Zimelidine first hit the market in 1982 .
Zimelidine was banned worldwide because of serious, sometimes fatal, cases of central and / or peripheral neuropathy , known as Guillain-Barré syndrome , and also because of a peculiar hypersensitivity reaction involving many organs, including pathological skin rashes: exanthema , flu-like symptoms, arthralgia , sometimes eosinophilia . In addition, the administration of zimelidine was associated with cases of increased suicidal thoughts and / or attempts in patients with depression. After the ban, this drug was replaced with fluvoxamine , fluoxetine and other SSRIs .
Mechanism of Action
The mechanism of action of zimelidine is a strong inhibition of serotonin reuptake from the synaptic cleft .
Medical Use
According to Monplezir and Godbu, zimelidine was also used effectively in the treatment of cataplexy in 1986 . [1] Zimelidine was able to improve cataplexy without causing daytime sleepiness. [one]
Side Effects
Possible side effects:
- dry mouth, dry throat and nasal membranes
- excessive sweating ( hyperhidrosis )
- dizziness
- nausea
Compatibility with other drugs
When used simultaneously with MAO inhibitors , the occurrence of serotonin syndrome is possible, which can lead to death.
Dosage
Previously, 200-400 mg per day was used for outpatients and 600 mg when taking the drug in an inpatient setting.
Notes
- ↑ 1 2 Godbout R., Montplaisir J. The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients (English) // Clinical Neuropharmacology : journal. - 1986. - Vol. 9 , no. 1 . - P. 46-51 . - DOI : 10.1097 / 00002826-198602000-00004 . - PMID 2950994 .